Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

Background: Emerging data suggests a possible role for cysteamine as an adjunct treatment for pulmonary exacerbations of cystic fibrosis (CF) that continue to be a major clinical challenge. There are no studies investigating the use of cysteamine in pulmonary exacerbations of CF. This exploratory ra...

Full description

Bibliographic Details
Main Authors: Bourke, S.J (Author), Daines, C.L (Author), Devereux, G. (Author), Doe, S. (Author), Dougherty, R. (Author), Franco, R. (Author), Fraser-Pitt, D.J (Author), Innes, A. (Author), Kopp, B.T (Author), Lascano, J. (Author), Layish, D. (Author), Lovie, E. (Author), Lucidi, V. (Author), MacGregor, G. (Author), Murray, L. (Author), O'Neil, D.A (Author), Peckham, D. (Author), Robertson, J. (Author), Wrolstad, D. (Author)
Format: Article
Language:English
Published: Public Library of Science 2021
Subjects:
Administration, Oral
adult
Adult
Article
bacterial load
C reactive protein
Chronic Respiratory Infection Symptom Score
controlled study
Cysteamine
cystic fibrosis
Cystic Fibrosis
Cystic Fibrosis Questionnaire
disease course
double blind procedure
drug effect
drug safety
drug tolerance
Europe
female
Female
forced expiratory volume
health care quality
human
Humans
inflammation
leukocyte count
lung
Lung
major clinical study
male
Male
Medication Adherence
medication compliance
mercaptamine
multicenter study
oral drug administration
patient-reported outcome
questionnaire
randomized controlled trial
safety
Safety
scoring system
sputum analysis
treatment duration
treatment outcome
United States
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items